title: Improving lipid control following myocardial infarction.
abstract: OBJECTIVE
  Following a myocardial infarction, lipid-lowering therapy is an established intervention to reduce the risk of recurrent cardiovascular events. Prior studies show a need to improve clinical practice in this area. Here, we review the latest research and perspectives on improving postmyocardial infarction lipid control.
  
  
  RESULTS
  Dyslipidemia and myocardial infarction remain leading causes of global disability and premature mortality throughout the world. The processes of care in lipid control involve multiple patient-level, provider-level, and healthcare system-level factors. They can be challenging to coordinate. Recent studies show suboptimal use of early high-intensity statin therapy and overall lipid control following myocardial infarction. Encouragingly, lipid control has improved over the last decade. Implementation science has identified checklists as an effective tool. At the top of the checklist for reducing atherogenic lipids and recurrent event risk postmyocardial infarction is early high-intensity statin therapy. Smoking cessation and participation in cardiac rehabilitation are also priorities, as are lifestyle counseling, promotion of medication adherence, ongoing lipid surveillance, and medication management.
  
  
  CONCLUSIONS
  Optimizing lipid control could further enhance clinical outcomes after myocardial infarction.
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland, USA.
authors.forename: Jyoti
authors.initials: J
authors.lastname: Ankam
authors.forename: David I
authors.initials: DI
authors.lastname: Feldman
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Blaha
authors.forename: Seth S
authors.initials: SS
authors.lastname: Martin
mesh_terms: D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control*; D064887:Observational Studies as Topic; D010349:Patient Compliance; D055502:Secondary Prevention
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents